JP2005523277A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005523277A5 JP2005523277A5 JP2003567437A JP2003567437A JP2005523277A5 JP 2005523277 A5 JP2005523277 A5 JP 2005523277A5 JP 2003567437 A JP2003567437 A JP 2003567437A JP 2003567437 A JP2003567437 A JP 2003567437A JP 2005523277 A5 JP2005523277 A5 JP 2005523277A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- cells
- regulator
- subject
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims 55
- 206010028980 Neoplasm Diseases 0.000 claims 41
- 239000003795 chemical substances by application Substances 0.000 claims 33
- 239000000427 antigen Substances 0.000 claims 25
- 102000036639 antigens Human genes 0.000 claims 25
- 108091007433 antigens Proteins 0.000 claims 25
- 239000012636 effector Substances 0.000 claims 25
- 230000000694 effects Effects 0.000 claims 19
- 238000004519 manufacturing process Methods 0.000 claims 16
- 201000011510 cancer Diseases 0.000 claims 12
- 238000000034 method Methods 0.000 claims 11
- 230000001154 acute effect Effects 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 7
- 230000002757 inflammatory effect Effects 0.000 claims 7
- 239000003550 marker Substances 0.000 claims 7
- 230000007423 decrease Effects 0.000 claims 6
- 230000001093 anti-cancer Effects 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 230000006870 function Effects 0.000 claims 5
- 230000004044 response Effects 0.000 claims 5
- 108010074051 C-Reactive Protein Proteins 0.000 claims 4
- 102100032752 C-reactive protein Human genes 0.000 claims 4
- 230000003915 cell function Effects 0.000 claims 4
- 230000000638 stimulation Effects 0.000 claims 4
- 210000004881 tumor cell Anatomy 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 230000004913 activation Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- FFRFGVHNKJYNOV-DOVUUNBWSA-N 3',4'-Anhydrovinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C=C(C2)CC)N2CCC2=C1NC1=CC=CC=C21 FFRFGVHNKJYNOV-DOVUUNBWSA-N 0.000 claims 1
- 108010041986 DNA Vaccines Proteins 0.000 claims 1
- 229940021995 DNA vaccine Drugs 0.000 claims 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 229950001104 anhydrovinblastine Drugs 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 230000003828 downregulation Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 230000009467 reduction Effects 0.000 claims 1
- 230000009261 transgenic effect Effects 0.000 claims 1
- 229960003048 vinblastine Drugs 0.000 claims 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPS0547A AUPS054702A0 (en) | 2002-02-14 | 2002-02-14 | Cancer therapy |
| PCT/AU2003/000187 WO2003068257A1 (en) | 2002-02-14 | 2003-02-14 | Cancer therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005523277A JP2005523277A (ja) | 2005-08-04 |
| JP2005523277A5 true JP2005523277A5 (https=) | 2005-12-22 |
Family
ID=3834147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003567437A Pending JP2005523277A (ja) | 2002-02-14 | 2003-02-14 | 癌の治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20050180971A1 (https=) |
| EP (2) | EP2100615B1 (https=) |
| JP (1) | JP2005523277A (https=) |
| CN (1) | CN1646155A (https=) |
| AU (2) | AUPS054702A0 (https=) |
| BR (1) | BR0307661A (https=) |
| CA (1) | CA2476366A1 (https=) |
| WO (1) | WO2003068257A1 (https=) |
| ZA (1) | ZA200407142B (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030228320A1 (en) * | 2000-08-18 | 2003-12-11 | Ashdown Martin Leonard | Retroviral immunotherapy |
| DE10347710B4 (de) | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Rekombinante Impfstoffe und deren Verwendung |
| EP1692516B1 (en) * | 2003-10-24 | 2010-12-01 | Immunaid Pty Ltd | Method of therapy |
| AU2004283322B2 (en) * | 2003-10-24 | 2010-09-16 | Biotempus Pty Ltd | Method of therapy |
| US20070275007A1 (en) * | 2003-11-05 | 2007-11-29 | The Government Of The United States Of America, Represented By The Secretary Of Health And Human S | Carbohydrate Antigen-Nanoparticle Conjugates and Uses Thereof as Antimetastatic Agents in Treating Cancer |
| EP1765402A2 (en) * | 2004-06-04 | 2007-03-28 | Duke University | Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity |
| AU2005282218B2 (en) * | 2004-09-08 | 2012-04-12 | Biotempus Pty Ltd | Therapeutic strategy for treating autoimmune and degenerative diseases |
| JP5386083B2 (ja) * | 2004-09-08 | 2014-01-15 | イミューンネイド ピーティーワイ リミテッド | 自己免疫疾患および変性疾患を治療する方法 |
| AU2006230099B2 (en) | 2005-03-25 | 2012-04-19 | Gitr, Inc. | GITR binding molecules and uses therefor |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| ES2776406T3 (es) * | 2007-07-12 | 2020-07-30 | Gitr Inc | Terapias de combinación que emplean moléculas de enlazamiento a GITR |
| DE102009015784A1 (de) * | 2009-03-31 | 2010-12-02 | Siemens Aktiengesellschaft | In-vitro-Verfahren zur Diagnostik von Tumorerkrankungen |
| WO2010135781A1 (en) | 2009-05-27 | 2010-12-02 | Immunaid Pty Ltd | Methods of treating diseases |
| HRP20211595T1 (hr) | 2011-05-24 | 2022-01-21 | BioNTech SE | Individualizirana cjepiva protiv raka |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| WO2014082729A1 (en) | 2012-11-28 | 2014-06-05 | Biontech Ag | Individualized vaccines for cancer |
| TWI693073B (zh) * | 2012-12-21 | 2020-05-11 | 日商中外製藥股份有限公司 | 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑 |
| WO2014180490A1 (en) | 2013-05-10 | 2014-11-13 | Biontech Ag | Predicting immunogenicity of t cell epitopes |
| CN113933504A (zh) | 2014-05-08 | 2022-01-14 | 中外制药株式会社 | 对gpc3靶向治疗剂疗法有效的患者施用的gpc3靶向治疗剂 |
| SG10201912986PA (en) | 2014-05-28 | 2020-02-27 | Agenus Inc | Anti-gitr antibodies and methods of use thereof |
| PT3151921T (pt) | 2014-06-06 | 2019-11-21 | Bristol Myers Squibb Co | Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos |
| WO2016045732A1 (en) | 2014-09-25 | 2016-03-31 | Biontech Rna Pharmaceuticals Gmbh | Stable formulations of lipids and liposomes |
| WO2016070051A2 (en) * | 2014-10-31 | 2016-05-06 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| WO2016128060A1 (en) | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
| MA44594B1 (fr) | 2015-05-29 | 2020-09-30 | Memorial Sloan Kettering Cancer Center | Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci |
| CA2988115A1 (en) | 2015-06-03 | 2016-12-08 | Bristol-Myers Squibb Company | Anti-gitr antibodies for cancer diagnostics |
| AU2016297249B2 (en) | 2015-07-23 | 2020-11-12 | Inhibrx Biosciences, Inc. | Multivalent and multispecific GITR-binding fusion proteins |
| WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
| BR112018010172A2 (pt) | 2015-11-19 | 2018-11-21 | Bristol Myers Squibb Co | anticorpos contra receptor de fator de necrose de tumor induzido por glicocorticoide (gitr) e usos dos mesmos |
| IL299072A (en) | 2015-12-02 | 2023-02-01 | Memorial Sloan Kettering Cancer Center | Antibodies and methods for using them |
| MA46770A (fr) | 2016-11-09 | 2019-09-18 | Agenus Inc | Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation |
| JOP20190100A1 (ar) | 2016-11-19 | 2019-05-01 | Potenza Therapeutics Inc | بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها |
| JP7106538B2 (ja) | 2016-12-07 | 2022-07-26 | アジェナス インコーポレイテッド | 抗体およびその使用方法 |
| WO2018106862A1 (en) | 2016-12-07 | 2018-06-14 | Agenus Inc. | Anti-ctla-4 antibodies and methods of use thereof |
| CN110869392A (zh) | 2017-05-16 | 2020-03-06 | 百时美施贵宝公司 | 用抗gitr激动性抗体治疗癌症 |
| WO2018224166A1 (en) | 2017-06-09 | 2018-12-13 | Biontech Rna Pharmaceuticals Gmbh | Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5308626A (en) | 1985-06-28 | 1994-05-03 | Toni N. Mariani | Lymphokine activated effector cells for antibody-dependent cellular cytotoxicity (ADCC) treatment of cancer and other diseases |
| US5141867A (en) * | 1987-02-02 | 1992-08-25 | E. I. Du Pont De Nemours And Company | Nucleotide sequence encoding a human immunodeficiency virus antigen |
| US5057423A (en) | 1987-12-18 | 1991-10-15 | University Of Pittsburgh | Method for the preparation of pure LAK-active lymphocytes |
| US20020094542A1 (en) * | 1988-04-15 | 2002-07-18 | Peter Leskovar | Drugs and methods for treating cancer |
| US5204466A (en) * | 1990-02-01 | 1993-04-20 | Emory University | Method and compositions for the synthesis of bch-189 and related compounds |
| US5643578A (en) | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
| US5358852A (en) * | 1992-12-21 | 1994-10-25 | Eastman Kodak Company | Use of calcium in immunoassay for measurement of C-reactive protein |
| ATE475668T1 (de) | 1994-01-27 | 2010-08-15 | Univ Massachusetts Medical | Immunisierung durch impfung von dns transkriptionseinheit |
| US5939400A (en) | 1996-02-26 | 1999-08-17 | The Board Of Trustees Of The Leland Stanford Junior University | DNA vaccination for induction of suppressive T cell response |
| US6110898A (en) * | 1996-05-24 | 2000-08-29 | University Of Maryland, Baltimore | DNA vaccines for eliciting a mucosal immune response |
| US20040203024A1 (en) * | 1996-06-06 | 2004-10-14 | Baker Brenda F. | Modified oligonucleotides for use in RNA interference |
| ZA975889B (en) * | 1996-07-08 | 1998-02-23 | Genentech Inc | HIV envelope polypeptides and vaccine. |
| US6107020A (en) * | 1996-09-20 | 2000-08-22 | Roger Williams Hospital | Model for protective and pathogenic roles of HIV-1 env-directed antibody dependent cellular cytotoxicity interaction with viral load, and uses thereof |
| US7030152B1 (en) * | 1997-04-02 | 2006-04-18 | The Brigham And Women's Hospital, Inc. | Systematic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atherosclerotic disease |
| GB2339200B (en) * | 1998-06-06 | 2001-09-12 | Genostic Pharma Ltd | Genostics |
| US20030228320A1 (en) * | 2000-08-18 | 2003-12-11 | Ashdown Martin Leonard | Retroviral immunotherapy |
| AUPQ948800A0 (en) | 2000-08-18 | 2000-09-07 | Immunaid Pty Ltd | A vaccine strategy |
| US20060134713A1 (en) * | 2002-03-21 | 2006-06-22 | Lifescan, Inc. | Biosensor apparatus and methods of use |
| ES2334125T3 (es) * | 2002-11-04 | 2010-03-05 | University Of Massachusetts | Interferencia de arn especifico de alelos. |
| EP2347767A3 (en) * | 2003-01-31 | 2013-06-12 | Albor Biologics, Inc. | Immune regulation based on the targeting of early activation molecules |
| EP1692516B1 (en) * | 2003-10-24 | 2010-12-01 | Immunaid Pty Ltd | Method of therapy |
| JP5386083B2 (ja) * | 2004-09-08 | 2014-01-15 | イミューンネイド ピーティーワイ リミテッド | 自己免疫疾患および変性疾患を治療する方法 |
| US7721198B2 (en) * | 2006-01-31 | 2010-05-18 | Microsoft Corporation | Story tracking for fixed layout markup documents |
| GB2436616A (en) * | 2006-03-29 | 2007-10-03 | Inverness Medical Switzerland | Assay device and method |
| WO2010135781A1 (en) * | 2009-05-27 | 2010-12-02 | Immunaid Pty Ltd | Methods of treating diseases |
-
2002
- 2002-02-14 AU AUPS0547A patent/AUPS054702A0/en not_active Abandoned
-
2003
- 2003-02-14 BR BR0307661-0A patent/BR0307661A/pt not_active IP Right Cessation
- 2003-02-14 EP EP09007539.1A patent/EP2100615B1/en not_active Revoked
- 2003-02-14 WO PCT/AU2003/000187 patent/WO2003068257A1/en not_active Ceased
- 2003-02-14 EP EP03701355A patent/EP1482970A4/en not_active Withdrawn
- 2003-02-14 CA CA002476366A patent/CA2476366A1/en not_active Abandoned
- 2003-02-14 CN CNA038082047A patent/CN1646155A/zh active Pending
- 2003-02-14 JP JP2003567437A patent/JP2005523277A/ja active Pending
- 2003-02-14 US US10/503,794 patent/US20050180971A1/en not_active Abandoned
- 2003-02-14 AU AU2003203051A patent/AU2003203051B2/en not_active Ceased
-
2004
- 2004-09-07 ZA ZA200407142A patent/ZA200407142B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005523277A5 (https=) | ||
| Xu et al. | Efficacy and mechanism of cGAMP to suppress Alzheimer’s disease by elevating TREM2 | |
| Yin et al. | Effect of low-dose radiation therapy on abscopal responses to hypofractionated radiation therapy and anti-PD1 in mice and patients with non-small cell lung cancer | |
| Murphy et al. | Efficacy of superoxide dismutase mimetic M40403 in attenuating radiation-induced oral mucositis in hamsters | |
| JP2021533787A5 (https=) | ||
| Steel et al. | Radiobiology of tumours | |
| US11684802B2 (en) | Reducing damage from radiation therapy and increasing cancer kill rates by interweaving of low and high dose sessions | |
| Shuryak et al. | Dose dependence of accelerated repopulation in head and neck cancer: Supporting evidence and clinical implications | |
| Barth et al. | Evaluation of TK1 targeting carboranyl thymidine analogs as potential delivery agents for neutron capture therapy of brain tumors | |
| US11419894B2 (en) | Modified natural killer cells for the treatment of cancer | |
| CN106166294A (zh) | 一种用于术前介入放疗治疗肿瘤的化合物 | |
| CN108379562B (zh) | 一种聚合物纳米佐剂及其制备方法和用途 | |
| Smilowitz et al. | Therapy model for advanced intracerebral B16 mouse melanoma using radiation therapy combined with immunotherapy | |
| CN107496434A (zh) | 芍药内酯苷作为吲哚胺2,3‑双加氧酶（ido）抑制剂的用途 | |
| US20220226474A1 (en) | Anti-fugetactic agent and anti-cancer agent combination therapy and compositions for the treatment of cancer | |
| US20210283255A1 (en) | Reducing Damage From Chemotherapy And Increasing Cancer Kill Rates By Using Interweaved Low Dose Radiation | |
| AU2024334390A1 (en) | Anti-tumor use of act001 composition | |
| Yang et al. | Intralesional Bacillus Calmette–Guérin injections and hypo-fractionated radiation synergistically induce systemic antitumor immune responses | |
| RU2524309C1 (ru) | Способ выбора тактики лечения местно-распространенного рака предстательной железы | |
| Abu-Gheida et al. | Radiobiology of stereotactic radiosurgery | |
| Mofid et al. | Lack of radioprotective efficacy of nanocurcumin in prostate cancer patients undergoing radiotherapy | |
| Rivina et al. | Radiation-induced lung cancers in murine models | |
| Langberg et al. | Influence of Fractionation Schedule on Development of Intestinal Complications Following Localized Irradiation: An experimental study in the rat | |
| KR20230166167A (ko) | ACE2 단백질이 과발현 유도된 근교계마우스(SARS-CoV2 임상 재현성 모델)에서 고선량 방사선에 따른 체내 면역세포의 손상과 면역세포의 공통 수용체(IL-2)의 중화 제어를 통한 면역 세포의 교란 억제 방법 | |
| Jeong | Investigating hyperactive NF-κB in glioma progression |